Caribou Biosciences, Inc.
CRBU- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001619856
No open-market purchases or sales by Caribou Biosciences, Inc. insiders were filed in the last 90 days; 137 institutions reported holding it in 13F filings for Q2 2026, worth $84.8M in total; Maverick Capital is the only superinvestor holding it.
Q1 2023 vs. Q4 2022
How the institutions holding Caribou Biosciences, Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Of which not filed for Q1 2023 | Q1 2023 | Change |
|---|---|---|---|---|
| Holders | 133 | 1 | 126 | −6 |
| Shares | 43.6M | 162 | 45.0M | +1.40M (+3.2%) |
| Value | $273.8M | $1.02K | $238.3M | −$35.5M (−13.0%) |
1 institution that held it in Q4 2022 haven't filed for Q1 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (13)
Institutions that held Caribou Biosciences, Inc. at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Bruce & Co., Inc. | 100,000 | $531.0K | 0.14% |
| Candriam Luxembourg S.C.A. | 85,556 | $418.2K | 0.00% |
| Renaissance Technologies LLC | 77,700 | $413.0K | 0.00% |
| Raymond James & Associates | 54,382 | $288.8K | 0.00% |
| Profund Advisors LLC | 43,585 | $231.4K | 0.01% |
| Jacobs Levy Equity Management, Inc | 32,220 | $171.1K | 0.00% |
| Prime Capital Investment Advisors, LLC | 26,331 | $139.8K | 0.01% |
| Saturna Capital CORP | 17,963 | $95.4K | 0.00% |
| BSW Wealth Partners | 13,464 | $71.5K | 0.01% |
| Price T Rowe Associates Inc | 10,546 | $56.0K | 0.00% |
| Aquatic Capital Management LLC | 1,600 | $8.00K | 0.00% |
| Ancora Advisors, LLC | 25 | $133 | 0.00% |
| Ellevest, Inc. | 4 | $21 | 0.00% |
Sold out (19)
Institutions that held Caribou Biosciences, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Shelton Capital Management | 160,700 | $1.01M |
| Two Sigma Investments, LP | 121,924 | $765.7K |
| Ensign Peak Advisors, Inc | 76,657 | $481.4K |
| State of Wisconsin Investment Board | 46,674 | $293.1K |
| Tudor Investment Corp Et Al | 29,997 | $188.0K |
| Qube Research & Technologies Ltd | 24,025 | $150.9K |
| Alpine Global Management, LLC | 17,442 | $110.0K |
| Bailard, Inc. | 14,216 | $89.3K |
| Bayesian Capital Management, LP | 13,900 | $87.3K |
| Engineers Gate Manager LP | 12,801 | $80.4K |
| Boulder Hill Capital Management LP | 11,400 | $71.6K |
| Arcus Capital Partners, LLC | 3,200 | $20.1K |
| Allspring Global Investments Holdings, LLC | 661 | $4.15K |
| Allworth Financial LP | 530 | $3.33K |
| Cubist Systematic Strategies, LLC | 247 | $1.55K |
| Signaturefd, LLC | 172 | $1.08K |
| Itau Unibanco Holding S.A. | 96 | $581 |
| Lindbrook Capital, LLC | 57 | $358 |
| Sofos Investments, Inc. | 6 | $6 |
Not filed for Q1 2023 yet (1)
Institutions that held Caribou Biosciences, Inc. at the end of Q4 2022 and haven't filed a 13F for Q1 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Sargent Bickham Lagudis LLC | 162 | $1.02K |